Vanguard Group Inc E Ffector Therapeutics, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.37 - $0.69 $63,043 - $117,567	170,387 Added 42.17%	574,413 $269,000
Q3 2023 Nov 14, 2023	SELL	$0.49 - $0.88 $927 - $1,665	-1,893 Reduced 0.47%	404,026 $242,000
Q1 2023 May 15, 2023	SELL	$0.35 - $0.67 $8,093 - $15,493	-23,124 Reduced 5.39%	405,919 $142,000
Q3 2022 Nov 14, 2022	SELL	$0.08 - $1.41 $7,020 - $123,734	-87,755 Reduced 16.98%	429,043 $245,000
Q1 2022 May 13, 2022	BUY	$3.85 - $8.2 $2,440 - $5,198	634 Added 0.12%	516,798 $2.07 Million
Q4 2021 Feb 14, 2022	BUY	$5.71 - $13.15 $2.95 Million - $6.79 Million	516,164 New	516,164 $4.27 Million

6.53M

Ticker EFTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,452,800
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.